US5741908A
(en)
|
1996-06-21 |
1998-04-21 |
Minnesota Mining And Manufacturing Company |
Process for reparing imidazoquinolinamines
|
UA67760C2
(uk)
|
1997-12-11 |
2004-07-15 |
Міннесота Майнінг Енд Мануфакчурінг Компані |
Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
|
US6110929A
(en)
*
|
1998-07-28 |
2000-08-29 |
3M Innovative Properties Company |
Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
|
US6518280B2
(en)
|
1998-12-11 |
2003-02-11 |
3M Innovative Properties Company |
Imidazonaphthyridines
|
ATE304852T1
(de)
|
1999-01-08 |
2005-10-15 |
3M Innovative Properties Co |
Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
|
US20020058674A1
(en)
|
1999-01-08 |
2002-05-16 |
Hedenstrom John C. |
Systems and methods for treating a mucosal surface
|
US6486168B1
(en)
|
1999-01-08 |
2002-11-26 |
3M Innovative Properties Company |
Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
|
US6558951B1
(en)
*
|
1999-02-11 |
2003-05-06 |
3M Innovative Properties Company |
Maturation of dendritic cells with immune response modifying compounds
|
US6451810B1
(en)
|
1999-06-10 |
2002-09-17 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6541485B1
(en)
|
1999-06-10 |
2003-04-01 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6331539B1
(en)
|
1999-06-10 |
2001-12-18 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
US6756382B2
(en)
|
1999-06-10 |
2004-06-29 |
3M Innovative Properties Company |
Amide substituted imidazoquinolines
|
US6573273B1
(en)
*
|
1999-06-10 |
2003-06-03 |
3M Innovative Properties Company |
Urea substituted imidazoquinolines
|
US6916925B1
(en)
|
1999-11-05 |
2005-07-12 |
3M Innovative Properties Co. |
Dye labeled imidazoquinoline compounds
|
US6376669B1
(en)
|
1999-11-05 |
2002-04-23 |
3M Innovative Properties Company |
Dye labeled imidazoquinoline compounds
|
JP3436512B2
(ja)
*
|
1999-12-28 |
2003-08-11 |
株式会社デンソー |
アクセル装置
|
US6894060B2
(en)
*
|
2000-03-30 |
2005-05-17 |
3M Innovative Properties Company |
Method for the treatment of dermal lesions caused by envenomation
|
EP1360486A2
(en)
*
|
2000-12-08 |
2003-11-12 |
3M Innovative Properties Company |
Screening method for identifying compounds that selectively induce interferon alpha
|
US6677348B2
(en)
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Aryl ether substituted imidazoquinolines
|
UA75622C2
(en)
|
2000-12-08 |
2006-05-15 |
3M Innovative Properties Co |
Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon
|
US6664265B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6664264B2
(en)
*
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US6545016B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Amide substituted imidazopyridines
|
US6660747B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Amido ether substituted imidazoquinolines
|
US6525064B1
(en)
|
2000-12-08 |
2003-02-25 |
3M Innovative Properties Company |
Sulfonamido substituted imidazopyridines
|
US6664260B2
(en)
|
2000-12-08 |
2003-12-16 |
3M Innovative Properties Company |
Heterocyclic ether substituted imidazoquinolines
|
US6545017B1
(en)
|
2000-12-08 |
2003-04-08 |
3M Innovative Properties Company |
Urea substituted imidazopyridines
|
US6677347B2
(en)
*
|
2000-12-08 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamido ether substituted imidazoquinolines
|
AU2006216669A1
(en)
*
|
2000-12-08 |
2006-08-31 |
3M Innovative Properties Company |
Compositions and methods for targeted delivery of immune response modifiers
|
US6660735B2
(en)
*
|
2000-12-08 |
2003-12-09 |
3M Innovative Properties Company |
Urea substituted imidazoquinoline ethers
|
US6667312B2
(en)
*
|
2000-12-08 |
2003-12-23 |
3M Innovative Properties Company |
Thioether substituted imidazoquinolines
|
US7226928B2
(en)
*
|
2001-06-15 |
2007-06-05 |
3M Innovative Properties Company |
Methods for the treatment of periodontal disease
|
EP1427445A4
(en)
*
|
2001-08-30 |
2006-09-06 |
3M Innovative Properties Co |
METHOD FOR MATURIZING PLASMACYTIDES DENDRITIC CELLS USING IMMUNE RESPONSE MODIFYING MOLECULES
|
JP2005519990A
(ja)
*
|
2001-10-12 |
2005-07-07 |
ユニバーシティ オブ アイオワ リサーチ ファウンデーション |
イミダゾキノリン化合物を用いて免疫応答を増強するための方法および産物
|
PT1719511E
(pt)
*
|
2001-11-16 |
2009-03-06 |
Coley Pharm Group Inc |
N-[4-(4-amino-2-etil-1h-imidazo[4,5-c]quinolina-1- -il)-butil]-metano-sulfonamida, uma composição farmacêutica que a contém e sua utilização
|
NZ532769A
(en)
*
|
2001-11-29 |
2005-12-23 |
3M Innovative Properties Co |
Pharmaceutical formulations comprising an immune response modifier
|
CA2365732A1
(en)
*
|
2001-12-20 |
2003-06-20 |
Ibm Canada Limited-Ibm Canada Limitee |
Testing measurements
|
US6677349B1
(en)
|
2001-12-21 |
2004-01-13 |
3M Innovative Properties Company |
Sulfonamide and sulfamide substituted imidazoquinolines
|
ATE373503T1
(de)
*
|
2002-02-06 |
2007-10-15 |
Ares Trading Sa |
Tumornekrosefaktor in kombination mit interferon in demyelinierungskrankheiten
|
CA2475595C
(en)
*
|
2002-02-22 |
2012-07-10 |
3M Innovative Properties Company |
Method of reducing and preventing uvb-induced immunosuppression
|
ATE491471T1
(de)
*
|
2002-03-19 |
2011-01-15 |
Powderject Res Ltd |
Adjuvantien für dns impstoffe basierend auf imidazochinoline
|
WO2003080112A2
(en)
*
|
2002-03-19 |
2003-10-02 |
Powdermed Limited |
Imidazoquinolineamines as adjuvants in hiv dna vaccination
|
IL164354A0
(en)
|
2002-04-04 |
2005-12-18 |
Coley Pharm Gmbh |
Immunostimulatory g,u-containing oligoribonucleotides
|
NZ537054A
(en)
*
|
2002-06-07 |
2006-10-27 |
3M Innovative Properties Co |
Ether substituted imidazopyridines
|
EP2269632B1
(en)
|
2002-08-15 |
2014-01-01 |
3M Innovative Properties Co. |
Immunostimulatory compositions and methods of stimulating an immune response
|
AU2003299082A1
(en)
*
|
2002-09-26 |
2004-04-19 |
3M Innovative Properties Company |
1h-imidazo dimers
|
AU2003287316A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Assays relating to toll-like receptor activity
|
AU2003287324A1
(en)
*
|
2002-12-11 |
2004-06-30 |
3M Innovative Properties Company |
Gene expression systems and recombinant cell lines
|
NZ540826A
(en)
|
2002-12-20 |
2008-07-31 |
3M Innovative Properties Co |
Aryl / hetaryl substituted imidazoquinolines
|
AU2003300184B8
(en)
|
2002-12-30 |
2009-12-03 |
3M Innovative Properties Company |
Immunostimulatory combinations
|
WO2004071459A2
(en)
*
|
2003-02-13 |
2004-08-26 |
3M Innovative Properties Company |
Methods and compositions related to irm compounds and toll-like receptor 8
|
US7485432B2
(en)
*
|
2003-02-27 |
2009-02-03 |
3M Innovative Properties Company |
Selective modulation of TLR-mediated biological activity
|
US8110582B2
(en)
|
2003-03-04 |
2012-02-07 |
3M Innovative Properties Company |
Prophylactic treatment of UV-induced epidermal neoplasia
|
US7163947B2
(en)
*
|
2003-03-07 |
2007-01-16 |
3M Innovative Properties Company |
1-Amino 1H-imidazoquinolines
|
WO2004080398A2
(en)
*
|
2003-03-07 |
2004-09-23 |
3M Innovative Properties Company |
1-amino 1h-imidazoquinolines
|
JP2006520245A
(ja)
|
2003-03-13 |
2006-09-07 |
スリーエム イノベイティブ プロパティズ カンパニー |
入れ墨の除去方法
|
CA2518282C
(en)
*
|
2003-03-13 |
2012-11-06 |
3M Innovative Properties Company |
Methods of improving skin quality
|
CA2518082C
(en)
*
|
2003-03-13 |
2013-02-12 |
3M Innovative Properties Company |
Methods for diagnosing skin lesions
|
US20040192585A1
(en)
|
2003-03-25 |
2004-09-30 |
3M Innovative Properties Company |
Treatment for basal cell carcinoma
|
US20040265351A1
(en)
*
|
2003-04-10 |
2004-12-30 |
Miller Richard L. |
Methods and compositions for enhancing immune response
|
EP1617871A4
(en)
*
|
2003-04-10 |
2010-10-06 |
3M Innovative Properties Co |
DISTRIBUTION OF IMMUNE-RESPONSE-MODIFYING COMPOUNDS USING PARTICULATE CARRIER MATERIALS CONTAINING METAL
|
US20040214851A1
(en)
*
|
2003-04-28 |
2004-10-28 |
3M Innovative Properties Company |
Compositions and methods for induction of opioid receptors
|
US7731967B2
(en)
|
2003-04-30 |
2010-06-08 |
Novartis Vaccines And Diagnostics, Inc. |
Compositions for inducing immune responses
|
WO2004110991A2
(en)
*
|
2003-06-06 |
2004-12-23 |
3M Innovative Properties Company |
PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
|
AR044466A1
(es)
*
|
2003-06-06 |
2005-09-14 |
3M Innovative Properties Co |
Proceso para la preparacion de imidazo [4,5-c] piridin-4-aminas
|
KR20060054371A
(ko)
*
|
2003-07-31 |
2006-05-22 |
쓰리엠 이노베이티브 프로퍼티즈 컴파니 |
캡슐화 및 제어된 방출을 위한 조성물
|
JP2007501252A
(ja)
*
|
2003-08-05 |
2007-01-25 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調整剤を含有する製剤
|
BRPI0412902A
(pt)
*
|
2003-08-12 |
2006-09-26 |
3M Innovative Properties Co |
compostos contendo imidazo substituìdo por oxima
|
CA2535338C
(en)
*
|
2003-08-14 |
2013-05-28 |
3M Innovative Properties Company |
Substituted 1h-imidazo[4,5-c]pyridin-4-amines,1h-imidazo[4,5-c]quinolin -4-amines and 1h-imidazo[4,5-c]naphthyridin-4-amines as immune response modifiers
|
CA2536249A1
(en)
*
|
2003-08-25 |
2005-03-10 |
3M Innovative Properties Company |
Delivery of immune response modifier compounds
|
JP2007504145A
(ja)
*
|
2003-08-25 |
2007-03-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫刺激性の組み合わせおよび治療
|
ES2406730T3
(es)
|
2003-08-27 |
2013-06-07 |
3M Innovative Properties Company |
Imidazoquinolinas sustituidas con ariloxi y arilalquilenoxi
|
CA2536578A1
(en)
*
|
2003-09-02 |
2005-03-10 |
3M Innovative Properties Company |
Methods related to the treatment of mucosal associated conditions
|
CA2537763A1
(en)
|
2003-09-05 |
2005-03-17 |
3M Innovative Properties Company |
Treatment for cd5+ b cell lymphoma
|
WO2005029037A2
(en)
*
|
2003-09-17 |
2005-03-31 |
3M Innovative Properties Company |
Selective modulation of tlr gene expression
|
US7544697B2
(en)
|
2003-10-03 |
2009-06-09 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and analogs thereof
|
RU2412942C2
(ru)
|
2003-10-03 |
2011-02-27 |
3М Инновейтив Пропертиз Компани |
Оксизамещенные имидазохинолины, способные модулировать биосинтез цитокинов
|
US20090075980A1
(en)
*
|
2003-10-03 |
2009-03-19 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridines and Analogs Thereof
|
JP2007508305A
(ja)
|
2003-10-03 |
2007-04-05 |
スリーエム イノベイティブ プロパティズ カンパニー |
ピラゾロピリジンおよびその類似物
|
JP2007509987A
(ja)
*
|
2003-10-31 |
2007-04-19 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫応答調節剤化合物による好中球活性化
|
AU2004291101A1
(en)
*
|
2003-11-14 |
2005-06-02 |
3M Innovative Properties Company |
Oxime substituted imidazo ring compounds
|
EP1682544A4
(en)
|
2003-11-14 |
2009-05-06 |
3M Innovative Properties Co |
HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
|
MY161812A
(en)
|
2003-11-25 |
2017-05-15 |
3M Innovative Properties Co |
Substituted imidazo ring systems and methods
|
AU2004293096A1
(en)
*
|
2003-11-25 |
2005-06-09 |
3M Innovative Properties Company |
Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US20050226878A1
(en)
*
|
2003-12-02 |
2005-10-13 |
3M Innovative Properties Company |
Therapeutic combinations and methods including IRM compounds
|
WO2005055932A2
(en)
*
|
2003-12-02 |
2005-06-23 |
3M Innovative Properties Company |
Therapeutic combinations and methods including irm compounds
|
CN1914203A
(zh)
*
|
2003-12-04 |
2007-02-14 |
3M创新有限公司 |
砜取代的咪唑环醚
|
EP1701955A1
(en)
|
2003-12-29 |
2006-09-20 |
3M Innovative Properties Company |
Arylalkenyl and arylalkynyl substituted imidazoquinolines
|
AU2004312510A1
(en)
*
|
2003-12-29 |
2005-07-21 |
3M Innovative Properties Company |
Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
|
AU2004312508A1
(en)
|
2003-12-30 |
2005-07-21 |
3M Innovative Properties Company |
Imidazoquinolinyl, imidazopyridinyl, and imidazonaphthyridinyl sulfonamides
|
EP1699398A4
(en)
*
|
2003-12-30 |
2007-10-17 |
3M Innovative Properties Co |
IMPROVING THE IMMUNE RESPONSE
|
CA2559607C
(en)
*
|
2004-03-15 |
2013-02-19 |
3M Innovative Properties Company |
Immune response modifier formulations and methods
|
AU2005228150A1
(en)
|
2004-03-24 |
2005-10-13 |
3M Innovative Properties Company |
Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
|
JP2007532572A
(ja)
*
|
2004-04-09 |
2007-11-15 |
スリーエム イノベイティブ プロパティズ カンパニー |
免疫反応調整剤を送達させるための方法、組成物および調製物
|
US20060051374A1
(en)
*
|
2004-04-28 |
2006-03-09 |
3M Innovative Properties Company |
Compositions and methods for mucosal vaccination
|
US20050267145A1
(en)
*
|
2004-05-28 |
2005-12-01 |
Merrill Bryon A |
Treatment for lung cancer
|
US20080015184A1
(en)
*
|
2004-06-14 |
2008-01-17 |
3M Innovative Properties Company |
Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
|
WO2005123080A2
(en)
|
2004-06-15 |
2005-12-29 |
3M Innovative Properties Company |
Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
|
US7897609B2
(en)
|
2004-06-18 |
2011-03-01 |
3M Innovative Properties Company |
Aryl substituted imidazonaphthyridines
|
US20070259907A1
(en)
*
|
2004-06-18 |
2007-11-08 |
Prince Ryan B |
Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
|
US8541438B2
(en)
|
2004-06-18 |
2013-09-24 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US7884207B2
(en)
*
|
2004-06-18 |
2011-02-08 |
3M Innovative Properties Company |
Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
|
US8026366B2
(en)
*
|
2004-06-18 |
2011-09-27 |
3M Innovative Properties Company |
Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
|
WO2006065280A2
(en)
|
2004-06-18 |
2006-06-22 |
3M Innovative Properties Company |
Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
|
EP1786450A4
(en)
*
|
2004-08-27 |
2009-11-11 |
3M Innovative Properties Co |
HIV IMMUNOSTIMATORY COMPOSITIONS
|
WO2006029115A2
(en)
|
2004-09-02 |
2006-03-16 |
3M Innovative Properties Company |
2-amino 1h imidazo ring systems and methods
|
WO2006026760A2
(en)
*
|
2004-09-02 |
2006-03-09 |
3M Innovative Properties Company |
1-amino imidazo-containing compounds and methods
|
CA2578741C
(en)
*
|
2004-09-02 |
2014-01-14 |
3M Innovative Properties Company |
1-alkoxy 1h-imidazo ring systems and methods
|
WO2006029223A2
(en)
*
|
2004-09-08 |
2006-03-16 |
Children's Medical Center Corporation |
Method for stimulating the immune response of newborns
|
WO2006031878A2
(en)
*
|
2004-09-14 |
2006-03-23 |
Novartis Vaccines And Diagnostics Inc. |
Imidazoquinoline compounds
|
WO2006042254A2
(en)
*
|
2004-10-08 |
2006-04-20 |
3M Innovative Properties Company |
Adjuvant for dna vaccines
|
US7557211B2
(en)
*
|
2004-11-12 |
2009-07-07 |
Bristol-Myers Squibb Company |
8H-imidazo[4,5-D]thiazolo[4,5-B]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
|
ES2377758T3
(es)
|
2004-11-12 |
2012-03-30 |
Bristol-Myers Squibb Company |
Compuestos tricíclicos basados en tiazolo[4,5-b]piridina imidazo-fusionada y composiciones farmacéuticas que los comprenden
|
WO2006063072A2
(en)
*
|
2004-12-08 |
2006-06-15 |
3M Innovative Properties Company |
Immunomodulatory compositions, combinations and methods
|
US8080560B2
(en)
*
|
2004-12-17 |
2011-12-20 |
3M Innovative Properties Company |
Immune response modifier formulations containing oleic acid and methods
|
JP2008526765A
(ja)
|
2004-12-30 |
2008-07-24 |
スリーエム イノベイティブ プロパティズ カンパニー |
皮膚転移の処置
|
AU2005326708C1
(en)
|
2004-12-30 |
2012-08-30 |
3M Innovative Properties Company |
Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
|
EP1830880A4
(en)
*
|
2004-12-30 |
2008-03-26 |
Coley Pharm Group Inc |
MULTI-CHANNEL ADMINISTRATION OF IMMUNE RESPONSE MODIFIER COMPOUNDS
|
JP5543068B2
(ja)
|
2004-12-30 |
2014-07-09 |
スリーエム イノベイティブ プロパティズ カンパニー |
キラル縮合[1,2]イミダゾ[4,5−c]環状化合物
|
US8436176B2
(en)
*
|
2004-12-30 |
2013-05-07 |
Medicis Pharmaceutical Corporation |
Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
|
NZ556399A
(en)
*
|
2004-12-30 |
2009-03-31 |
Takeda Pharmaceutical |
1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1H-imidazo[4,5-C][1,5]naphthyridin-4-amine methanesulfonate
|
US9248127B2
(en)
|
2005-02-04 |
2016-02-02 |
3M Innovative Properties Company |
Aqueous gel formulations containing immune response modifiers
|
AU2006212765B2
(en)
*
|
2005-02-09 |
2012-02-02 |
3M Innovative Properties Company |
Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
|
CA2602083A1
(en)
|
2005-02-09 |
2006-08-09 |
Coley Pharmaceutical Group, Inc. |
Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
|
US7968563B2
(en)
|
2005-02-11 |
2011-06-28 |
3M Innovative Properties Company |
Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
|
CA2597446A1
(en)
|
2005-02-11 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Substituted imidazoquinolines and imidazonaphthyridines
|
WO2006089264A2
(en)
|
2005-02-18 |
2006-08-24 |
Novartis Vaccines And Diagnostics Inc. |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
CA2598437A1
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Method of preferentially inducing the biosynthesis of interferon
|
EP1851220A2
(en)
|
2005-02-23 |
2007-11-07 |
3M Innovative Properties Company |
Hydroxyalkyl substituted imidazonaphthyridines
|
WO2006091567A2
(en)
|
2005-02-23 |
2006-08-31 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinoline compounds and methods
|
CA2598695A1
(en)
|
2005-02-23 |
2006-09-21 |
Coley Pharmaceutical Group, Inc. |
Hydroxyalkyl substituted imidazoquinolines
|
WO2006099275A2
(en)
|
2005-03-14 |
2006-09-21 |
3M Innovative Properties Company |
Method of treating actinic keratosis
|
EP1869043A2
(en)
|
2005-04-01 |
2007-12-26 |
Coley Pharmaceutical Group, Inc. |
Pyrazolopyridine-1,4-diamines and analogs thereof
|
EP1863814A1
(en)
|
2005-04-01 |
2007-12-12 |
Coley Pharmaceutical Group, Inc. |
1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
|
EP1874345B1
(en)
*
|
2005-04-25 |
2012-08-15 |
3M Innovative Properties Company |
Immunostimulatory compositions
|
US20100017895A1
(en)
|
2005-07-18 |
2010-01-21 |
Amy Weiner |
Small animal model for hcv replication
|
AU2006287270A1
(en)
|
2005-09-09 |
2007-03-15 |
Coley Pharmaceutical Group, Inc. |
Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
|
ZA200803029B
(en)
*
|
2005-09-09 |
2009-02-25 |
Coley Pharm Group Inc |
Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
|
US8889154B2
(en)
|
2005-09-15 |
2014-11-18 |
Medicis Pharmaceutical Corporation |
Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
|
US8258191B2
(en)
*
|
2005-10-31 |
2012-09-04 |
Coloplast A/S |
Topical skin barriers and methods of evaluation thereof
|
CA2628131C
(en)
|
2005-11-04 |
2012-03-20 |
Coley Pharmaceutical Group, Inc. |
Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
|
NZ567978A
(en)
|
2005-11-04 |
2011-09-30 |
Novartis Vaccines & Diagnostic |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
EP1951298A1
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Adjuvanted influenza vaccines including cytokine-inducing agents
|
EP2368572B1
(en)
|
2005-11-04 |
2020-03-04 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
PT2478916T
(pt)
|
2006-01-27 |
2020-07-03 |
Seqirus Uk Ltd |
Vacinas de influenza que contêm hemaglutinina e proteínas da matriz
|
EP1988896A4
(en)
|
2006-02-22 |
2011-07-27 |
3M Innovative Properties Co |
CONJUGATES TO MODIFY IMMUNE REACTIONS
|
EP2001881A2
(en)
*
|
2006-03-07 |
2008-12-17 |
Endacea, Inc. |
Compositions and methods for treating respiratory disorders
|
US8329721B2
(en)
|
2006-03-15 |
2012-12-11 |
3M Innovative Properties Company |
Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
|
CA2646891A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
WO2007109810A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
CA2646539A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Imidazoquinoxaline compounds as immunomodulators
|
EP2382987A1
(en)
|
2006-03-24 |
2011-11-02 |
Novartis Vaccines and Diagnostics GmbH |
Storage of influenza vaccines without refrigeration
|
SG173336A1
(en)
|
2006-03-31 |
2011-08-29 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
WO2008008432A2
(en)
|
2006-07-12 |
2008-01-17 |
Coley Pharmaceutical Group, Inc. |
Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
|
WO2008010963A2
(en)
*
|
2006-07-18 |
2008-01-24 |
3M Innovative Properties Company |
Immune response modifier formulations
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
US8124096B2
(en)
*
|
2006-07-31 |
2012-02-28 |
3M Innovative Properties Company |
Immune response modifier compositions and methods
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
PL2061765T3
(pl)
|
2006-09-01 |
2015-04-30 |
Senhwa Biosciences Inc |
Modulatory białkowych kinaz serynowo-treoninowych i PARP
|
US8178539B2
(en)
|
2006-09-06 |
2012-05-15 |
3M Innovative Properties Company |
Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
|
EP3456348A1
(en)
|
2006-09-11 |
2019-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
CN101568351B
(zh)
*
|
2006-12-22 |
2012-05-30 |
3M创新有限公司 |
控制释放的组合物和方法
|
US20080149123A1
(en)
*
|
2006-12-22 |
2008-06-26 |
Mckay William D |
Particulate material dispensing hairbrush with combination bristles
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2484377A1
(en)
|
2007-06-27 |
2012-08-08 |
Novartis AG |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2217236A1
(en)
*
|
2007-11-02 |
2010-08-18 |
Yaupon Therapeutics, Inc. |
Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
KR20100135766A
(ko)
|
2008-03-18 |
2010-12-27 |
노파르티스 아게 |
인플루엔자 바이러스 백신 항원 제조의 개선
|
PT2382474E
(pt)
|
2009-01-20 |
2015-06-03 |
Transgene Sa |
Icam-1 solúvel como biomarcador para a previsão de uma resposta terapêutica
|
EP2403526B1
(en)
|
2009-03-06 |
2019-05-15 |
GlaxoSmithKline Biologicals SA |
Chlamydia antigens
|
MX2011010061A
(es)
|
2009-03-24 |
2011-11-18 |
Transgene Sa |
Biomarcador para monitorear pacientes.
|
MX2011010050A
(es)
|
2009-03-25 |
2011-12-14 |
Univ Texas |
Composiciones para estimulación de resistencia inmune innata de mamiferos a patógenos.
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
MX2011010920A
(es)
|
2009-04-17 |
2011-11-04 |
Transgene Sa |
Biomarcador para monitorear pacientes.
|
KR20120027276A
(ko)
|
2009-04-27 |
2012-03-21 |
노파르티스 아게 |
인플루엔자를 예방하기 위한 면역증강된 백신
|
NZ596325A
(en)
|
2009-07-10 |
2013-11-29 |
Transgene Sa |
Biomarker for selecting patients and related methods
|
HRP20220756T1
(hr)
|
2009-07-15 |
2022-09-02 |
Glaxosmithkline Biologicals S.A. |
Proteinski pripravci rsv f i postupci za izradu istih
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
US20110033515A1
(en)
*
|
2009-08-04 |
2011-02-10 |
Rst Implanted Cell Technology |
Tissue contacting material
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US9242980B2
(en)
|
2010-08-17 |
2016-01-26 |
3M Innovative Properties Company |
Lipidated immune response modifier compound compositions, formulations, and methods
|
AU2011340063B2
(en)
*
|
2010-12-09 |
2016-03-24 |
Kasina Laila Innova Pharmaceuticals Private Limited |
Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
|
EP4159232A1
(en)
|
2011-01-26 |
2023-04-05 |
GlaxoSmithKline Biologicals S.A. |
Rsv immunization regimen
|
ES2691745T3
(es)
|
2011-04-08 |
2018-11-28 |
Janssen Sciences Ireland Uc |
Derivados de pirimidina para el tratamiento de infecciones víricas
|
RS56748B1
(sr)
|
2011-05-13 |
2018-03-30 |
Glaxosmithkline Biologicals Sa |
Pre-fuzioni rsv f antigeni
|
MX347240B
(es)
|
2011-06-03 |
2017-04-20 |
3M Innovative Properties Co |
Ligadores heterobifuncionales con segmentos polietilenglicol y conjugados modificadores de la respuesta inmunitaria elaborados a partir de los mismos.
|
JP6415979B2
(ja)
|
2011-06-03 |
2018-10-31 |
スリーエム イノベイティブ プロパティズ カンパニー |
ヒドラジノ1h−イミダゾキノリン−4−アミン及びこれから調製された複合体
|
US20130023736A1
(en)
|
2011-07-21 |
2013-01-24 |
Stanley Dale Harpstead |
Systems for drug delivery and monitoring
|
PE20141359A1
(es)
*
|
2011-10-21 |
2014-10-13 |
Glaxosmithkline Llc |
Compuestos y metodos para mejorar las respuestas inmunitarias innatas
|
MX354924B
(es)
|
2011-11-07 |
2018-03-22 |
Novartis Ag |
Molecula portadora que comprende un antigeno spr0096 y un spr2021.
|
US9556176B2
(en)
|
2011-11-09 |
2017-01-31 |
Janssen Sciences Ireland Uc |
Purine derivatives for the treatment of viral infections
|
WO2013108272A2
(en)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Blood stage malaria vaccine
|
KR20200075023A
(ko)
|
2012-05-04 |
2020-06-25 |
화이자 인코포레이티드 |
전립선 관련된 항원 및 백신 기재 면역치료 요법
|
KR102207888B1
(ko)
|
2012-07-13 |
2021-01-26 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염증의 치료를 위한 거대환식 푸린
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
AU2013301450B2
(en)
|
2012-08-10 |
2018-01-18 |
Janssen Sciences Ireland Uc |
Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
|
SG11201502622VA
(en)
|
2012-10-10 |
2015-05-28 |
Janssen Sciences Ireland Uc |
PYRROLO[3,2-<i>D</i>]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES
|
EP2925729B1
(en)
|
2012-11-16 |
2017-10-18 |
Janssen Sciences Ireland UC |
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
|
HUE051988T2
(hu)
|
2013-01-07 |
2021-04-28 |
Univ Pennsylvania |
Készítmények és eljárások bõr T-sejt lymphoma kezelésére
|
US9598378B2
(en)
|
2013-02-21 |
2017-03-21 |
Janssen Sciences Ireland Uc |
2-aminopyrimidine derivatives for the treatment of viral infections
|
US9072747B2
(en)
|
2013-03-10 |
2015-07-07 |
Peritech Pharma Ltd. |
Topical compositions and methods of treatment of anorectal disorders
|
EA202090547A3
(ru)
|
2013-03-29 |
2020-12-30 |
Янссен Сайенсиз Айрлэнд Юси |
Макроциклические деаза-оксипурины для лечения вирусных инфекций
|
MY188071A
(en)
|
2013-05-24 |
2021-11-16 |
Janssen Sciences Ireland Uc |
Pyridone derivatives for the treatment of viral infections and further diseases
|
US10385054B2
(en)
|
2013-06-27 |
2019-08-20 |
Janssen Sciences Ireland Unlimited Company |
Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
|
EP3024476A1
(en)
|
2013-07-26 |
2016-06-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
SG11201510736PA
(en)
|
2013-07-30 |
2016-02-26 |
Janssen Sciences Ireland Uc |
THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
|
AU2014347059B2
(en)
|
2013-11-05 |
2017-09-07 |
Solventum Intellectual Properties Company |
Sesame oil based injection formulations
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
CN114716555A
(zh)
|
2014-01-10 |
2022-07-08 |
博笛生物科技有限公司 |
靶向表达egfr的肿瘤的化合物和组合物
|
US10421971B2
(en)
|
2014-01-15 |
2019-09-24 |
The University Of Chicago |
Anti-tumor therapy
|
SI3122378T1
(sl)
|
2014-03-26 |
2020-03-31 |
Glaxosmithkline Biologicals S.A. |
Mutantni stafilokokni antigeni
|
WO2015193506A1
(en)
|
2014-06-20 |
2015-12-23 |
Institut Pasteur Korea |
Anti-infective compounds
|
AU2015286043B2
(en)
|
2014-07-09 |
2020-08-20 |
Birdie Biopharmaceuticals Inc. |
Anti-PD-L1 combinations for treating tumors
|
CN105233291A
(zh)
|
2014-07-09 |
2016-01-13 |
博笛生物科技有限公司 |
用于治疗癌症的联合治疗组合物和联合治疗方法
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
WO2016180274A1
(zh)
*
|
2015-05-09 |
2016-11-17 |
江苏新元素医药科技有限公司 |
用于治疗或预防乳腺癌的化合物
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
WO2016187459A1
(en)
|
2015-05-20 |
2016-11-24 |
The Regents Of The University Of California |
Method for generating human dendritic cells for immunotherapy
|
MX2018002017A
(es)
|
2015-08-31 |
2018-03-26 |
3M Innovative Properties Co |
Compuestos de anillo de imidazo[4,5-c] sustituido con guanidina.
|
EP3344623B1
(en)
|
2015-08-31 |
2021-02-17 |
3M Innovative Properties Company |
Imidazo[4,5-c]ring compounds containing substituted guanidine groups
|
US10526309B2
(en)
|
2015-10-02 |
2020-01-07 |
The University Of North Carolina At Chapel Hill |
Pan-TAM inhibitors and Mer/Axl dual inhibitors
|
AU2016343682A1
(en)
|
2015-10-30 |
2018-06-14 |
The Regents Of The University Of California |
Methods of generating T-cells from stem cells and immunotherapeutic methods using the T-cells
|
CN115554406A
(zh)
|
2016-01-07 |
2023-01-03 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-cd20组合
|
CN115350279A
(zh)
|
2016-01-07 |
2022-11-18 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-her2组合
|
CN115252792A
(zh)
|
2016-01-07 |
2022-11-01 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-egfr组合
|
IL299285A
(en)
|
2016-05-16 |
2023-02-01 |
Access To Advanced Health Inst |
Formulation containing a TLR agonist and methods of use
|
IL313085A
(en)
|
2016-05-16 |
2024-07-01 |
Access To Advanced Health Inst |
Pegylated liposomes and methods of use
|
JP7171444B2
(ja)
|
2016-07-01 |
2022-11-15 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
ウイルス感染治療用のジヒドロピラノピリミジン
|
EP3504215B1
(en)
|
2016-08-26 |
2022-04-06 |
3M Innovative Properties Company |
Fused [1,2]imidazo[4,5-c]ring compounds substituted with guanidino groups
|
CA3033542A1
(en)
|
2016-08-30 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Compositions and uses of biomaterials and activators of innate immunity
|
KR102450287B1
(ko)
|
2016-09-29 |
2022-09-30 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
바이러스 감염 및 추가적인 질환의 치료를 위한 피리미딘 프로드러그
|
US11826422B2
(en)
|
2016-11-09 |
2023-11-28 |
Board Of Regents, The University Of Texas System |
Methods and compositions for adaptive immune modulation
|
KR102279347B1
(ko)
|
2016-12-15 |
2021-07-21 |
한국생명공학연구원 |
피리딘계 화합물을 유효성분으로 함유하는 dyrk 관련 질환의 예방 또는 치료용 약학적 조성물
|
WO2018160552A1
(en)
|
2017-03-01 |
2018-09-07 |
3M Innovative Properties Company |
IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS
|
CN108794467A
(zh)
|
2017-04-27 |
2018-11-13 |
博笛生物科技有限公司 |
2-氨基-喹啉衍生物
|
AR111760A1
(es)
|
2017-05-19 |
2019-08-14 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
|
MX2019015744A
(es)
|
2017-06-23 |
2020-02-20 |
Birdie Biopharmaceuticals Inc |
Composiciones farmaceuticas.
|
EP4257198A3
(en)
|
2017-08-22 |
2023-10-18 |
Dynavax Technologies Corporation |
Alkyl chain modified imidazoquinoline derivatives as tlr7/8 agonists and uses thereof
|
WO2019099412A1
(en)
|
2017-11-14 |
2019-05-23 |
Dynavax Technologies Corporation |
Cleavable conjugates of tlr7/8 agonist compounds, methods for preparation, and uses thereof
|
US11306083B2
(en)
|
2017-12-20 |
2022-04-19 |
3M Innovative Properties Company |
Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier
|
CN111788202B
(zh)
|
2018-02-28 |
2024-03-01 |
3M创新有限公司 |
具有N-1支链基团的经取代的咪唑并[4,5-c]喹啉化合物
|
BR112020016859A2
(pt)
|
2018-02-28 |
2020-12-29 |
Pfizer Inc. |
Variantes de il-15 e usos da mesma
|
TW201945003A
(zh)
|
2018-03-01 |
2019-12-01 |
愛爾蘭商健生科學愛爾蘭無限公司 |
2,4-二胺基喹唑啉衍生物及其醫學用途
|
CA3097865A1
(en)
|
2018-04-25 |
2019-10-31 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
BR112020022897A2
(pt)
|
2018-05-23 |
2021-02-23 |
Pfizer Inc. |
anticorpos específicos para cd3 e usos dos mesmos
|
BR112020022595A2
(pt)
|
2018-05-23 |
2021-02-09 |
Pfizer Inc. |
anticorpos específicos para gucy2c e usos dos mesmos
|
US11884662B2
(en)
|
2018-05-24 |
2024-01-30 |
3M Innovative Properties Company |
N-1 branched cycloalkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
EP3887369B1
(en)
|
2018-11-26 |
2024-05-08 |
Solventum Intellectual Properties Company |
N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
US20220370606A1
(en)
|
2018-12-21 |
2022-11-24 |
Pfizer Inc. |
Combination Treatments Of Cancer Comprising A TLR Agonist
|
EP3980415A1
(en)
|
2019-06-06 |
2022-04-13 |
3M Innovative Properties Company |
N-1 branched alkyl substituted imidazo[4,5-c]quinoline compounds, compositions, and methods
|
CN113906027A
(zh)
|
2019-06-12 |
2022-01-07 |
3M创新有限公司 |
具有N-1支链基团的苯乙基取代的咪唑并[4,5-c]喹啉化合物
|
WO2021116420A1
(en)
|
2019-12-13 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Use of tlr7 and/or tlr8 agonists for the treatment of leptospirosis
|
EP4077387A1
(en)
|
2019-12-17 |
2022-10-26 |
Pfizer Inc. |
Antibodies specific for cd47, pd-l1, and uses thereof
|
JP2023533011A
(ja)
|
2020-07-08 |
2023-08-01 |
スリーエム イノベイティブ プロパティズ カンパニー |
N-1分岐イミダゾキノリン、そのコンジュゲート、及び方法
|
WO2022009157A1
(en)
|
2020-07-10 |
2022-01-13 |
Novartis Ag |
Lhc165 and spartalizumab combinations for treating solid tumors
|
MX2023000662A
(es)
|
2020-07-17 |
2023-02-27 |
Pfizer |
Anticuerpos terapeuticos y sus usos.
|
WO2022130046A1
(en)
|
2020-12-16 |
2022-06-23 |
3M Innovative Properties Company |
N-1 branched imidazoquinolines, conjugates thereof, and methods
|
WO2023111726A1
(en)
|
2021-12-14 |
2023-06-22 |
3M Innovative Properties Company |
N-1 triazole substituted imidazoquinolines, conjugates thereof, and methods
|